A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Responsive to HCTZ 25 mg

NCT00219115 Phase 3 COMPLETED

To evaluate the blood pressure lowering effects of the combination of aliskiren 300 mg and HCTZ 25 mg in obese patients with essential hypertension inadequately treated with HCTZ 25 mg, compared to irbesartan or amlodipine with HCTZ or HCTZ alone.

Details

Lead sponsor	Novartis
Phase	Phase 3
Status	COMPLETED
Enrolment	493
Start date	2005-01
Completion	2006-03

Conditions

• Hypertension

Interventions

• aliskiren

Primary outcomes

• Change from baseline in mean sitting diastolic blood pressure after 8 weeks

Countries

United States, Germany